BMC Cancer · 2017 · 91 citations · 40 references
MedicineMolecular BiologyOncologyBreast OncologyMolecular DiagnosticsMolecular OncologyBreast PathologyCancer BiomarkersCancer Molecular DiagnosticsImmunohistochemistryMolecular Tumor ProfilingTherapy Response AssessmentBreast Cancer Response AssessmentDiagnostic Testing AccuracyFormalin-fixed Paraffin-embedded Tissue AnalysisInter-observer AgreementNeoadjuvant Clinical TrialsNeoadjuvant Therapy TrialsParaffin-embedded Tissue StainingPredictive Marker Assessment
BACKGROUND: Proliferation may predict response to neoadjuvant therapy of breast cancer and is commonly assessed by manual scoring of slides stained by immunohistochemistry (IHC) for Ki-67 similar to ER and PgR. This method carries significant intra- and inter-observer variability. Automatic scoring of Ki-67 with digital image analysis (qIHC) or assessment of MKI67 gene expression with RT-qPCR may improve diagnostic accuracy. METHODS: Ki-67 IHC visual assessment was compared to the IHC nuclear tool (AperioTM) on core biopsies from a randomized neoadjuvant clinical trial. Expression of ESR1, PGR and MKI67 by RT-qPCR was performed on RNA extracted from the same formalin-fixed paraffin-embedded tissue. Concordance between the three methods (vIHC, qIHC and RT-qPCR) was assessed for all 3 markers. The potential of Ki-67 IHC and RT-qPCR to predict pathological complete response (pCR) was evaluated using ROC analysis and non-parametric Mann-Whitney Test. RESULTS: Correlation between methods (qIHC versus RT-qPCR) was high for ER and PgR (spearman´s r = 0.82, p < 0.0001 and r = 0.86, p < 0.0001, respectively) resulting in high levels of concordance using predefined cut-offs. When comparing qIHC of ER and PgR with RT-qPCR of ESR1 and PGR the overall agreement was 96.6 and 91.4%, respectively, while overall agreement of visual IHC with RT-qPCR was slightly lower for ER/ESR1 and PR/PGR (91.2 and 92.9%, respectively). In contrast, only a moderate correlation was observed between qIHC and RT-qPCR continuous data for Ki-67/MKI67 (Spearman's r = 0.50, p = 0.0001). Up to now no predictive cut-off for Ki-67 assessment by IHC has been established to predict response to neoadjuvant chemotherapy. Setting the desired sensitivity at 100%, specificity for the prediction of pCR (ypT0ypN0) was significantly higher for mRNA than for protein (68.9% vs. 22.2%). Moreover, the proliferation levels in patients achieving a pCR versus not differed significantly using MKI67 RNA expression (Mann-Whitney p = 0.002), but not with qIHC of Ki-67 (Mann-Whitney p = 0.097) or vIHC of Ki-67 (p = 0.131). CONCLUSION: Digital image analysis can successfully be implemented for assessing ER, PR and Ki-67. IHC for ER and PR reveals high concordance with RT-qPCR. However, RT-qPCR displays a broader dynamic range and higher sensitivity than IHC. Moreover, correlation between Ki-67 qIHC and RT-qPCR is only moderate and RT-qPCR with MammaTyper® outperforms qIHC in predicting pCR. Both methods yield improvements to error-prone manual scoring of Ki-67. However, RT-qPCR was significantly more specific.
40
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Joel S. Parker, Michael E. Mullins, Maggie C.U. Cheang et al. · Journal of Clinical Oncology · 2009 · 4.9K citations · Full text
Medicine, Bioinformatics, Oncology +16
M. Elizabeth H. Hammond, Daniel F. Hayes, Mitch Dowsett et al. · Journal of Clinical Oncology · 2010 · 4.3K citations · Full text
Medicine, Cancer Biology, Oncology +14
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Stefan Aebi, T. Davidson, Günther Gruber et al. · Annals of Oncology · 2010 · 2.9K citations · Full text